Full history for every metric is available with a Kvantra account
BenevolentAI S.A. (BAI.AS)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | £m | 7 | 5 | 7 | 5 | 11 | 7 |
| Operating profit | £m | -78 | |||||
| Net profit | £m | -27 | -48 | -55 | -86 | -164 | -63 |
| EPS reported | £ | -0.58 | |||||
| Operating cashflow per share | £ | -0.52 | |||||
| Capex per share | £ | 0.01 | |||||
| FCF per share | £ | -0.53 | |||||
| Free cash flow | £m | -58 | |||||
| Net debt | £m | -36 | |||||
| Book value equity | £m | 94 | |||||
| Book value per share | £ | 0.86 | |||||
| Number of shares | m | 109.11 | |||||
| DPS (TTM paid) | £ | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 1.08 | |||||
| P/S LTM | x | 13.93 | |||||
| P/FCF LTM | x | -1.75 | |||||
| EV/EBITDA LTM | x | -1.01 | |||||
| EV/Sales LTM | x | 9.60 | |||||
| Earnings Yield LTM | % | -62.01% | |||||
| FCF Yield | % | -57.03% | |||||
| Quality | |||||||
| ROE | % | -67.16% | |||||
| ROIC | % | -67.80% | |||||
| Operating margin | % | -1058.2% | |||||
| Gross margin | % | 100.00% | |||||
| FCF/Sales | % | -794.28% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -30.58% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -12.26 | |||||
| Net Debt/EBITDA | x | 0.46 | |||||
| EBIT/Net interest | x | -237.95 | |||||
| Net debt/market cap | % | -35.72% | |||||
| Net debt/Equity | x | -0.39 | |||||
| Gross debt/equity | x | 0.05 | |||||
Company overview
BenevolentAI S.A. is a clinical-stage company focused on drug discovery and development, powered by artificial intelligence. Its unique BenevolentAI platform supports an extensive internal pipeline of pharmaceutical programs. The company addresses a broad array of therapeutic areas, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral conditions, oncology, Parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. Through a collaboration with AstraZeneca, BenevolentAI aims to deepen understanding of complex disease biology and identify novel targets. Founded in 2013, the enterprise is headquartered in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BenevolentAI S.A. (BAI.AS)
BenevolentAI S.A. is a clinical-stage company focused on drug discovery and development, powered by artificial intelligence. Its unique BenevolentAI platform supports an extensive internal pipeline of pharmaceutical programs. The company addresses a broad array of therapeutic areas, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral conditions, oncology, Parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. Through a collaboration with AstraZeneca, BenevolentAI aims to deepen understanding of complex disease biology and identify novel targets. Founded in 2013, the enterprise is headquartered in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free